TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07612488: A Study of CS231295 in Patients With Advanced Solid Tumors

Sponsor: ThalassaX Therapeutics United States Ltd · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 42 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,570,800

Rescue Site Savings

+$1,036,728

Unlock Full NCT07612488 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07612488 Rescue Dossier →